Q2 FY27 revenue up 54.6%, EBITDA positive; FY28 store target 800

Management guided margin improvementManagement guided margin pressureInvestor Communications View source PDF Explain this filing

ZOTA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-0.8%Reaction day

₹1225.00

prior close

₹1239.00

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+2.2%-3.0% vs market

Pharmaceuticals peers, median of 173sector+0.8%-1.6% vs sector

On the reaction day the stock moved 3.0 pts less than Nifty Microcap 250 and 1.6 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.6

10m

-0.8

15m

-1.0

30m

-1.5

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-0.8+2.2-3.0+0.8-1.6

Next day

-0.5+3.3-3.9+1.6-2.1

+0.7pendingpending+1.5-0.8

—————

15d

—————

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 173Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Q2 FY27 revenue rose 54.6% to Rs 199.33 crore, while EBITDA turned positive at Rs 7.92 crore versus a Rs 9.55 crore loss in Q1. Net loss narrowed to Rs 25.96 crore from Rs 43.94 crore. Davaindia sales increased 76.3% to Rs 168.47 crore, with 2,840 stores. Management targets 600-650 store additions in FY27 and 800 in FY28. Gross margin was 60.17%; input costs may keep margins under pressure for a quarter, with recovery seen over 3-4 quarters.

Likely market impact

Revenue growth and EBITDA may support sentiment, but losses and input-cost margin pressure remain risks. Rapid store expansion adds execution risk.